Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Adma Biologics (ADMA) over the last 5 years, with Dec 2024 value amounting to $0.81.

  • Adma Biologics' EPS (Weighted Average and Diluted) changed negligibly% to $0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.86, marking a year-over-year increase of 207.14%. This contributed to the annual value of $0.81 for FY2024, which is 723.08% up from last year.
  • Adma Biologics' EPS (Weighted Average and Diluted) amounted to $0.81 in FY2024, which was up 723.08% from -$0.13 recorded in FY2023.
  • In the past 5 years, Adma Biologics' EPS (Weighted Average and Diluted) ranged from a high of $0.81 in FY2024 and a low of -$0.88 during FY2020.
  • Over the past 3 years, Adma Biologics' median EPS (Weighted Average and Diluted) value was -$0.13 (recorded in 2023), while the average stood at $0.12.
  • Data for Adma Biologics' EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 723.08% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Adma Biologics' EPS (Weighted Average and Diluted) stood at -$0.88 in 2020, then skyrocketed by 42.05% to -$0.51 in 2021, then spiked by 35.29% to -$0.33 in 2022, then spiked by 60.61% to -$0.13 in 2023, then surged by 723.08% to $0.81 in 2024.